{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:28:25Z","timestamp":1795026505857,"version":"4.10.2"},"reference-count":25,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,3,10]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual conference and trainee symposium, the status of psoriatic disease (PsD) biomarkers was discussed in a workshop. The significant heterogeneity of PsD causes disease management to be very challenging, but biomarkers can prove helpful in disease diagnosis, stratification, and precision medicine. Although a few potential biomarkers have been discovered, none have been fully validated. Recent studies have used omic technologies that show promise but need further verification and validation. Many challenges remain, but the anticipated results of studies being conducted by recently established large consortia may lead to the identification of clinically actionable biomarkers.<\/jats:p>","DOI":"10.3899\/jrheum.2024-0260","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T12:15:14Z","timestamp":1721045714000},"page":"74-76","source":"Crossref","is-referenced-by-count":9,"title":["Biomarkers in Psoriasis and Psoriatic Arthritis: Where Are We Now?"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0275","authenticated-orcid":false,"given":"Vinod","family":"Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7883-6439","authenticated-orcid":false,"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3848-5122","authenticated-orcid":false,"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"2024120403401085000_51.Suppl_2.74.1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.12688\/f1000research.19144.1","article-title":"Psoriatic arthritis","volume":"8","author":"Ocampo","year":"2019","journal-title":"F1000Res"},{"key":"2024120403401085000_51.Suppl_2.74.2","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1093\/rheumatology\/keac078","article-title":"Defining imaging sub-phenotypes of psoriatic arthritis: integrative analysis of imaging data and gene expression in a PsA patient cohort","volume":"61","author":"Eder","year":"2022","journal-title":"Rheumatology"},{"key":"2024120403401085000_51.Suppl_2.74.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218186"},{"key":"2024120403401085000_51.Suppl_2.74.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.003"},{"key":"2024120403401085000_51.Suppl_2.74.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.004"},{"key":"2024120403401085000_51.Suppl_2.74.6","doi-asserted-by":"crossref","first-page":"1759720X211014010","DOI":"10.1177\/1759720X211014010","article-title":"Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review","volume":"13","author":"Magee","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024120403401085000_51.Suppl_2.74.7","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113989"},{"key":"2024120403401085000_51.Suppl_2.74.8","doi-asserted-by":"publisher","DOI":"10.1177\/009286150704100504"},{"key":"2024120403401085000_51.Suppl_2.74.9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/apm.12934","article-title":"Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases","volume":"127","author":"Litman","year":"2019","journal-title":"APMIS"},{"key":"2024120403401085000_51.Suppl_2.74.10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41582-020-0362-2","article-title":"Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities","volume":"16","author":"Davis","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"2024120403401085000_51.Suppl_2.74.11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4137\/BIC.S33380","article-title":"Predicting clinical outcomes using molecular biomarkers","volume":"8","author":"Burke","year":"2016","journal-title":"Biomark Cancer"},{"key":"2024120403401085000_51.Suppl_2.74.12","doi-asserted-by":"crossref","unstructured":"Pepe M , Janes H. Methods for evaluating prediction performance of biomarkers and tests. In: Lee MLT , Gail M , Pfeiffer R , Satten G , Cai T , Gandy A , editors. Risk assessment and evaluation of predictions. New York: Springer; 2013:107-42.","DOI":"10.1007\/978-1-4614-8981-8_7"},{"key":"2024120403401085000_51.Suppl_2.74.13","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1235"},{"key":"2024120403401085000_51.Suppl_2.74.14","doi-asserted-by":"crossref","first-page":"1054539","DOI":"10.3389\/fimmu.2022.1054539","article-title":"Biomarkers in psoriatic arthritis: a meta-analysis and systematic review","volume":"13","author":"Wirth","year":"2022","journal-title":"Front Immunol"},{"key":"2024120403401085000_51.Suppl_2.74.15","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1038\/s41467-018-06672-6","article-title":"Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients","volume":"9","author":"Patrick","year":"2018","journal-title":"Nat Commun"},{"key":"2024120403401085000_51.Suppl_2.74.16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/art.41899","article-title":"Identification and evaluation of serum protein biomarkers that differentiate psoriatic arthritis from rheumatoid arthritis","volume":"74","author":"McArdle","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024120403401085000_51.Suppl_2.74.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214737"},{"key":"2024120403401085000_51.Suppl_2.74.18","doi-asserted-by":"crossref","first-page":"835760","DOI":"10.3389\/fimmu.2022.835760","article-title":"Combined single cell transcriptome and surface epitope profiling identifies potential biomarkers of psoriatic arthritis and facilitates diagnosis via machine learning","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"2024120403401085000_51.Suppl_2.74.19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2019.0098","article-title":"Association of HLA-C*06:02 status with differential response to ustekinumab in patients with psoriasis: a systematic review and meta-analysis","volume":"155","author":"van Vugt","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2024120403401085000_51.Suppl_2.74.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.038"},{"key":"2024120403401085000_51.Suppl_2.74.21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology"},{"key":"2024120403401085000_51.Suppl_2.74.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78866-2"},{"key":"2024120403401085000_51.Suppl_2.74.23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003042"},{"key":"2024120403401085000_51.Suppl_2.74.24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41584-022-00748-w","article-title":"HIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis","volume":"18","author":"FitzGerald","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024120403401085000_51.Suppl_2.74.25","unstructured":"National Institute of Arthritis and Musculoskeletal and Skin Diseases . Accelerating Medicines Partnership\u00ae Autoimmune and Immune-Mediated Diseases (AMP\u00ae AIM) Program. [Internet. Accessed March 21, 2024.] Available from: www.niams.nih.gov\/grants-funding\/niams-supported-research-programs\/accelerating-medicines-partnership-amp"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:41:30Z","timestamp":1733312490000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":25,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.3899\/jrheum.2024-0260"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0260","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}